According to Fortune Business Insights, the global precision oncology market size was valued at USD 122.60 billion in 2025 and is projected to grow from USD 133.06 billion in 2026 to USD 317.16 billion by 2034, exhibiting a CAGR of 11.47% during the forecast period. North America dominated the precision oncology market with a market share of 39.07% in 2025.
The precision oncology market is growing as cancer diagnosis and treatment increasingly focus on the molecular and genetic characteristics of individual tumors. Precision oncology uses genomic profiling, biomarker testing, advanced diagnostics, and targeted treatments to help healthcare professionals select therapies based on a patient's specific cancer characteristics.
Key Market Drivers
Increasing Demand for Personalized Cancer Treatment
The growing recognition that cancers can differ significantly in their molecular characteristics is encouraging the adoption of precision oncology. Traditional treatment approaches may not provide the same outcomes for every patient, making molecular profiling and biomarker assessment increasingly important in selected cancer types.
Advancements in Genomic Profiling and Liquid Biopsy
Technological improvements in genomic sequencing, molecular diagnostics, and liquid biopsy are expanding the range of tools available for cancer assessment. Comprehensive genomic profiling can evaluate multiple genetic alterations within a tumor, while liquid biopsy techniques analyze tumor-associated biomarkers in blood and other bodily fluids.
Growing Development of Targeted Therapies and Immunotherapies
Pharmaceutical and biotechnology companies are increasingly developing medicines designed to target specific molecular alterations or immune-related characteristics of tumors. Targeted therapies act on particular biological pathways involved in cancer development, while biomarker-guided immunotherapies use relevant biomarkers to help identify patients who may benefit from immune-based treatments.
Market Restraints
High Costs of Genomic Testing and Targeted Treatments
Comprehensive genomic profiling, advanced molecular diagnostics, and targeted cancer therapies can involve substantial costs. Testing expenses may include laboratory infrastructure, specialized equipment, bioinformatics, sample processing, and interpretation of complex molecular results.
Limited Access to Testing and Interpretation Expertise
Precision oncology depends on the availability of reliable diagnostic testing and the ability to interpret molecular findings within a clinical context. Some healthcare facilities may lack specialized laboratories, advanced sequencing infrastructure, or personnel with expertise in genomic medicine.
Get Sample PDF Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/precision-oncology-market-116082
Market Opportunities
Expansion of Comprehensive Genomic Profiling
Comprehensive genomic profiling creates opportunities for diagnostic providers by enabling the evaluation of multiple genetic alterations through a single testing approach. This can help clinicians identify potentially actionable biomarkers and assess treatment options for eligible patients.
Growing Adoption of Biomarker-Guided Therapies
The development of new targeted medicines and immunotherapies is creating opportunities for companion diagnostics and biomarker testing. These diagnostic tools can help determine whether a patient meets the biomarker criteria associated with a particular therapy.
Increasing Use of Liquid Biopsy Technologies
Liquid biopsy technologies offer opportunities for cancer assessment and monitoring by analyzing tumor-associated material in blood and other bodily fluids. Depending on the clinical application, these tests may help identify molecular alterations, monitor changes over time, or provide additional information when tissue sampling is challenging.
Segmentation
By Type
- Diagnostics
- Companion Diagnostics
- Comprehensive Genomic Profiling
- Liquid Biopsy Assays
- Single Biomarker Tests
- Others
- Therapeutics
- Targeted Therapies
- Biomarker-Guided Immunotherapies
- Others
By Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Hematologic Malignancies
- Others
By End User
- Hospitals & Cancer Centers
- Diagnostic Laboratories
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Others
Uncover Japan’s Market Trends - Explore the Latest - Precision Oncology Market - Insights
Regional Insights
North America
North America dominated the precision oncology market with a 39.07% share in 2025. The region benefits from advanced healthcare infrastructure, established cancer research networks, and the adoption of genomic testing and targeted treatments.
Europe
Europe represents an important market for precision oncology, supported by cancer research initiatives, established healthcare systems, and increasing interest in personalized medicine. Hospitals, diagnostic laboratories, and research institutions are adopting genomic profiling and biomarker testing to support cancer diagnosis and treatment selection.
Asia Pacific
Asia Pacific offers significant growth opportunities as healthcare infrastructure expands and awareness of molecular diagnostics increases. Investments in cancer research, genomic testing capabilities, and advanced oncology treatments are supporting market development across the region.
Rest of the World
Markets across Latin America, the Middle East, and Africa may present opportunities as healthcare providers expand cancer diagnostic capabilities and improve access to specialized treatments. Investments in oncology centers, laboratory infrastructure, and clinical research can support the gradual adoption of precision medicine.
Get Sample PDF Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/precision-oncology-market-116082
Key Players in the Precision Oncology Market
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- QIAGEN N.V.
- Abbott Laboratories
- Agilent Technologies, Inc.
- Guardant Health, Inc.
- Foundation Medicine, Inc.
- Exact Sciences Corporation
- AstraZeneca plc
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Novartis AG
- Pfizer Inc.
Conclusion
The precision oncology market is expected to expand as cancer care increasingly incorporates molecular diagnostics, genomic profiling, and treatments tailored to individual tumor characteristics. Advances in liquid biopsy, companion diagnostics, targeted therapies, and biomarker-guided immunotherapies are creating opportunities across the healthcare and pharmaceutical industries.